News
Welcome to the news and media section of our website, where we feature corporate news releases and media coverage of interest.
Show by Tag
An abstract has been presented at the 2023 AETA & CETA/ACTE Joint Convention in Orlando, FL summarizing a study showing a positive effect of MCWF (Amplimune) on pregnancy per embryo transfer for dairy cows with one lactation.
Data from a U.S. study using NovaVive's immunotherapy for equine endometritis, Settle®, to treat endometrial cups was presented today at the International Symposium on Equine Reproduction (ISER) in Foz do Iguaçu, Brazil.
Effective in June, 2023, all over-the-counter bovine antibiotics in the U.S. will be switched to prescription-only status. Amplimune immunotherapy offers an alternative to antibiotics that does not require a prescription.
NovaVive offers a USDA-approved immunotherapeutic, Equimune®, which has been recommended as a preventative treatment in horses exposed to Equine Herpes Virus (EHV-1). EHV-1 outbreaks are occurring with increasing frequency.
NovaVive's immunotherapy for calf scours - Amplimune® - is now available in the New Zealand market. The product was approved for sale by Agricultural Compounds and Veterinary Medicines (ACVM) last September.
An abstract being presented at the 2021 IETS Virtual Conference summarizes data from a study showing 45% of Amplimune-treated embryo transfer recipient heifers achieved pregnancy at Day 60 vs. 28% of untreated controls.